China channel feed – Endpoints News

China channel feed

AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron

2 months ago

Ascendis’ China joint venture, Visen Pharmaceuticals, prices $86M Hong Kong IPO

2 months ago

WuXi AppTec's US revenue growth continues to dip in post-Biosecure environment

2 months ago

Merck KGaA says earlier moves to localize manufacturing help ease Trump tariff impact

2 months ago

China bans imports of Illumina's DNA sequencers following US tariffs

2 months ago

En vogue Chinese ADC biotech lets Hong Kong IPO filing lapse

2 months ago

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

3 months ago

How Keymed steered the China-to-US NewCo model in biotech

3 months ago

AstraZeneca buys FibroGen’s China unit for local control of anemia drug

3 months ago

FDA puts two Chinese API makers on import alert after failed inspections

3 months ago

Trump’s tariff impact likely ‘minimal’ for brand-name drugmakers, manufacturing partners

3 months ago

Post-Hoc: China tensions both help and hurt Illumina

3 months ago

AstraZeneca offers some detail on China probe, reaffirms commitment to that market

3 months ago

Merck CEO says he’s confident in growth despite Gardasil ‘headwind’

3 months ago

Illumina added to China's blacklist following Biosecure Act, tariffs

3 months ago

Updated: Merck temporarily pauses Gardasil shipments to China following sales slowdown

3 months ago

Biogen’s revised research strategy is to avoid becoming obsolete, top exec says

3 months ago

Novo Nordisk’s amycretin prompts 22% weight loss in early obesity trial

4 months ago

Chinese startup begins first trial of in vivo CRISPR therapy for blood disease

4 months ago

Oncology biotech ArriVent does another China ADC deal, this time with Lepu Biopharma

4 months ago

China's biotech boom is threatening US drugmakers' dominance

4 months ago

Ascentage estimates $133M in proceeds as it plans Nasdaq dual listing

4 months ago

Another US biotech emerges with drug candidate from China-based Keymed

4 months ago

Post-Hoc: The embryo editing debate is back

4 months ago

First page Previous page 123 4 5 Next page Last page